preview

Differences in Cancer Stem Cell Properties in Human Colon Cancer Cell Lines HCT116 and HT29

Best Essays
Summary:
Background and objective. Tumor heterogeneity is shown to be related to clinical outcome in cancer patients. The concept of a small subset of cancer stem cells being responsible for tumor relapse and metastasis comes out as a promising strategy for targeted cancer therapy. However, cancer stem cells are not easy to identify and isolate. The aim of this study was to determine the putative colon cancer stem cell subsets in human colon cancer cell lines HCT116 and HT29, which differ in their aggressiveness and differentiation capacity. Material and methods. Flow cytometry was used to asses HCT116 and HT29 cell lines for the expression of stemness-associated surface markers CD24, CD44, CD117, CD133, ESA, ABCB1. Both cell lines were treated with 5-fluoruracil and the phenotype of chemoresistant cells was investigated. Side population was visualized via Rhodamine 123 staining. Relative expression of ABCG2, c-Myc and Oct4 genes was quantified using qPCR analysis. Results and conclusions. It was shown that HCT116 and HT29 cell lines differ in their stemness-related properties. We imply that putative CSC subset for HCT116 cell line is CD44+/CD24-/CD133- (4,1% of all cells) and for HT29 cells – CD24+/CD44-/CD133- (4,9% of all cells).

Keywords: tumor heterogeneity, colon cancer, cancer stem cells, HCT116, HT29

Introduction
The concept of tumor heterogeneity being related to the course of the disease and clinical outcome in cancer patients draws additional attention in the era of personalized medicine (1). Current cancer treatment strategies are based on the site of origin of the primary tumor. However, it was shown that tumors developed from distinct cell types differ in their prognosis and response to cytotoxic therapies (2...

... middle of paper ...

...ozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111-5.
25. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. The Journal of clinical investigation. 2008;118(6):2111-20.
26. Ke J, Wu X, Wu X, He X, Lian L, Zou Y, et al. A subpopulation of CD24(+) cells in colon cancer cell lines possess stem cell characteristics. Neoplasma. 2012;59(3):282-8.
27. Du L, Wang HY, He LY, Zhang JY, Ni BY, Wang XH, et al. CD44 is of Functional Importance for Colorectal Cancer Stem Cells. Clin Cancer Res. 2008;14(21):6751-60.
28. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity. Clin Dev Immunol. 2012.
Get Access